Mobile

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either ...

Mise à jour : Il y a 4 ans
Référence : NCT02397395

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis

Femme et Homme

  • | Pays :
  • France
  • Spain
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The purpose of this study is to evaluate the percentage of participants with sustained virologic response 12 weeks after the actual end of study treatment (SVR12)

Critère d'inclusion

  • Renal Impairment ,End stage renal disease

Liens